256-270 of 878
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Balazs Halmos, MD, MS
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Project Oncology®Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Kathleen Moore, MD, MS
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Project Oncology®Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Kathleen Moore, MD, MS
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Project Oncology®Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Kathleen Moore, MD, MS
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Project Oncology®Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Marlene Mimi Maeusli, PhD.
Redefining Cancer Care with Functional Precision Medicine
Project Oncology®Redefining Cancer Care with Functional Precision Medicine
Matt Birnholz, MD
Jim Foote, MBA
- advertisement
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Project Oncology®Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Ryan Quigley
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Ryan Quigley
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Brian Slomovitz, MD
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
- advertisement
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerPutting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP
Giancarlo Moscol, M.D.
Apremilast in Patients with a History of Cancer: A Five-Year Clinical Perspective
Clinician's RoundtableApremilast in Patients with a History of Cancer: A Five-Year Clinical Perspective
